.jpg)
.png)
All
Coconut oil consumption is rapidly increasing. This increase is in part because of supposed health benefits, including relieving mental fatigue and depression, altering risk factors of cardiovascular disease, and modifying cognition.1 Despite limited evidence for these purported benefits,... more
.v-center { display: flex; align-items: flex-start; justify-content: center; flex-grow: 1; width: 390px; padding: 10px } .flex-row { display: flex; flex-wrap: wrap; justify-content: center; } .well { width: 100%; } .v-center-small... more
The most significant advance in clinical lipidology and preventive cardiology in 2015 is the availability of proprotein convertase subtilisin-like kexin type 9 (PCSK9) monoclonal antibody (mAb) therapy. This potent breakthrough therapy has garnered as much excitement as the release of statin... more
Amgen announced today that the FOURIER trial met its primary and secondary endpoints in evaluating whether evolocumab reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) without new safety issues. Amgen also announced that the... more
The 2015 Impact Factors were recently released and the Journal of Clinical Lipidology (JCL) saw yet another significant increase — from 3.904 (2014) to 4.906 (2015). The Journal is now ranked 23rd out of 253 journals in its category (pharmacology and pharmacy... more
This issue sponsored by the Northeast Lipid Association Managing Patients with Statin Myopathy and Rhabdomyolysis Legacy of Periodic Monitoring of Liver Function Tests in Patients on Chronic Statin Therapy
The National Lipid Association ("NLA") plays an important role in reaching out to healthcare professionals, patients, and other groups. Our members guide research, discover new therapies, and engage in high quality medical practice. The NLA offers educational opportunities that help translate... more
Clinical Insights: The Impact of Supplements/Nutraceuticals (Functional Foods) on Lipid Levels: What Works? And How Well?
It is a great time to be a clinical lipidologist and I want to thank all of the readers for a wonderful year as co-editor of LipidSpin! It has been the year of the PCSK9 inhibitor introduction and that has captured everyone’s attention. But that is not all that is going on in clinical lipidology;... more
The NLA has consistently held a determined focus on promoting the highest levels of education and professional development. We are defined by the quality of our outstanding leadership, members, partners and staff. As a result, we are continuously challenged to assess and refine our work in an... more